• 5-(N,N-dimethyl)-Amiloride: Advancing NHE1 Inhibitor Rese...

  2026-03-05

  5-(N,N-dimethyl)-Amiloride hydrochloride from APExBIO offers unmatched selectivity and potency for Na+/H+ exchanger research, enabling breakthroughs in endothelial and cardiac dysfunction studies. Discover workflow enhancements, troubleshooting strategies, and translational applications that set this NHE1 inhibitor apart.

• ABT-888 (Veliparib): Potent PARP Inhibitor for DNA Repair...

  2026-03-05

  ABT-888 (Veliparib) is a potent and selective PARP1 and PARP2 inhibitor used in research to sensitize tumor cells to chemotherapy and radiation. As a tool for DNA repair inhibition, ABT-888 is especially effective in microsatellite instability (MSI) tumor models, with a well-defined mechanism of action and robust preclinical benchmarks.

• AZD2461 (SKU A4164): Scenario-Driven Solutions for Reliab...

  2026-03-04

  This article delivers an evidence-based, scenario-driven guide to overcoming real laboratory challenges when using AZD2461 (SKU A4164), a next-generation PARP inhibitor. Drawing on validated protocols and peer-reviewed findings, we explore how AZD2461 addresses assay reproducibility, workflow optimization, and drug resistance in breast cancer research. Designed for biomedical researchers and lab technicians, this resource grounds every recommendation in quantitative data and practical laboratory experience.

• Olaparib (AZD2281): Selective PARP-1/2 Inhibitor for BRCA...

  2026-03-04

  Olaparib (AZD2281) is a highly potent and selective PARP-1/2 inhibitor widely used in BRCA-deficient cancer research and DNA damage response assays. It enables targeted studies of homologous recombination deficiency and radiosensitization in preclinical models. This dossier details its mechanism of action, benchmarks, and integration into cancer research workflows.

• BMN 673: Potent PARP1/2 Inhibitor for DNA Repair Deficien...

  2026-03-03

  BMN 673 (Talazoparib) stands out as a selective PARP inhibitor for cancer therapy, offering unparalleled efficacy in targeting homologous recombination deficient cancer models. This comprehensive guide details experimental workflows, advanced applications, and troubleshooting strategies to maximize research outcomes with BMN 673 from APExBIO.

• Influenza Hemagglutinin (HA) Peptide: Advanced Strategies...

  2026-03-03

  Explore how Influenza Hemagglutinin (HA) Peptide enables next-generation protein purification and mechanistic discovery. This article details the HA tag peptide's biophysical properties, competitive binding mechanisms, and advanced applications—offering a uniquely integrative perspective for molecular biology research.

• Optimizing DNA Damage Response Assays with Olaparib (AZD2...

  2026-03-02

  This scenario-driven guide addresses key challenges in DNA damage response and cytotoxicity assays using Olaparib (AZD2281, Ku-0059436) (SKU A4154). Drawing on recent literature and validated workflows, this article equips biomedical researchers and lab technicians to enhance reproducibility and interpretability in BRCA-deficient cancer research.

• ABT-888 (Veliparib): Potent PARP1/2 Inhibitor for DNA Rep...

  2026-03-02

  ABT-888 (Veliparib) is a potent and selective poly (ADP-ribose) polymerase (PARP1/2) inhibitor used to sensitize cancer cells to chemotherapy and radiation. This article details its mechanism, benchmarks, and integration strategies for DNA repair inhibition research.

• Optimizing DNA Repair Assays with BMN 673 (Talazoparib) P...

  2026-03-01

  This article provides scenario-driven, evidence-based guidance for biomedical researchers using BMN 673 (Talazoparib) Potent PARP1/2 Inhibitor (SKU A4153) in cell viability and cytotoxicity workflows. Drawing on peer-reviewed data and practical laboratory experience, it addresses conceptual, protocol, and vendor-selection challenges, positioning SKU A4153 as a high-performing, reliable reagent for DNA repair deficiency targeting and homologous recombination deficient cancer research.

• AZD2461: Novel PARP Inhibitor Empowering Breast Cancer Re...

  2026-02-28

  AZD2461 is a next-generation poly (ADP-ribose) polymerase inhibitor that uniquely overcomes Pgp-mediated drug resistance and induces robust cell cycle arrest in breast cancer models. Leveraging advanced workflows and troubleshooting insights, researchers can maximize the impact of AZD2461 from in vitro assays to translational preclinical studies.

• 5-(N,N-dimethyl)-Amiloride (hydrochloride): Selective NHE...

  2026-02-27

  5-(N,N-dimethyl)-Amiloride (hydrochloride) is a potent Na+/H+ exchanger inhibitor, widely used to dissect intracellular pH regulation and sodium ion transport. Data show its high selectivity for NHE1 and protective effects in ischemia-reperfusion models. This article clarifies its molecular action, benchmarks, and translational potential in cardiovascular and endothelial research.

• Olaparib (AZD2281): Next-Generation PARP-1/2 Inhibitor fo...

  2026-02-27

  Explore the molecular mechanisms and innovative research applications of Olaparib (AZD2281), a selective PARP-1/2 inhibitor for BRCA-deficient cancer research. This article uniquely examines localized delivery strategies and the integration of nanotechnology for enhanced targeted therapy.

• Olaparib (AZD2281): Selective PARP Inhibitor for BRCA-Def...

  2026-02-26

  Olaparib (AZD2281) revolutionizes BRCA-deficient cancer research by precisely targeting PARP-mediated DNA repair pathways, enabling advanced DNA damage response and tumor radiosensitization studies. Its robust performance in both in vitro and in vivo models empowers researchers to unravel therapeutic vulnerabilities and optimize targeted therapy protocols. Streamline your cancer research workflows with APExBIO's high-quality Olaparib.

• 5-(N,N-dimethyl)-Amiloride Hydrochloride: Mechanisms, Evi...

  2026-02-26

  5-(N,N-dimethyl)-Amiloride hydrochloride is a potent, selective Na+/H+ exchanger inhibitor used in cardiovascular and pH regulation research. This article synthesizes peer-reviewed data and product benchmarks to clarify its mechanisms, research applications, and key limitations. Its high selectivity for NHE1/2/3 makes it central to studies of intracellular pH, ischemia-reperfusion injury, and endothelial dysfunction.

• Harnessing Olaparib (AZD2281, Ku-0059436): Mechanistic In...

  2026-02-25

  This thought-leadership article explores the mechanistic underpinnings and translational opportunities of Olaparib (AZD2281, Ku-0059436), a potent PARP-1/2 inhibitor, for BRCA-deficient cancer research. Beyond standard product descriptions, it integrates peer-reviewed evidence, highlights innovative delivery strategies, and offers actionable strategic guidance for researchers advancing DNA damage response assays, tumor radiosensitization, and targeted therapy development.

254 records 6/17 page Previous Next First page 上5页 678910 下5页 Last page